Hepatology InternationalPub Date : 2026-10-01Epub Date: 2026-02-26DOI: 10.1007/s12072-026-11073-9
Jiehua Han, Xiaoyan Zhang
{"title":"Comment on \"BRIX1 activated by mTORC1-SP1 signaling regulates ribosome biogenesis and alternative splicing to promote hepatocellular carcinoma progression\".","authors":"Jiehua Han, Xiaoyan Zhang","doi":"10.1007/s12072-026-11073-9","DOIUrl":"10.1007/s12072-026-11073-9","url":null,"abstract":"","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":"1553-1554"},"PeriodicalIF":7.8,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147289788","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Hepatology InternationalPub Date : 2026-10-01Epub Date: 2026-03-30DOI: 10.1007/s12072-026-11080-w
Yuanqin Zhang, Yang He, Yifei Chen, Fang Nie
{"title":"Re-examining the incremental benefit of TACE-TKI-PD-1 triplet therapy: time-related bias and treatment pathways in a real-world HCC cohort.","authors":"Yuanqin Zhang, Yang He, Yifei Chen, Fang Nie","doi":"10.1007/s12072-026-11080-w","DOIUrl":"10.1007/s12072-026-11080-w","url":null,"abstract":"","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":"1555-1556"},"PeriodicalIF":7.8,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147581288","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Hepatology InternationalPub Date : 2026-10-01Epub Date: 2026-06-23DOI: 10.1007/s12072-026-11112-5
Ji Won Han, Seunghee Na, Kyungdo Han, Kyu Na Lee, Do Young Kim, Sang Hoon Ahn, Mi Na Kim
{"title":"Alcohol consumption and dementia risk in steatotic liver disease: a nationwide cohort study.","authors":"Ji Won Han, Seunghee Na, Kyungdo Han, Kyu Na Lee, Do Young Kim, Sang Hoon Ahn, Mi Na Kim","doi":"10.1007/s12072-026-11112-5","DOIUrl":"10.1007/s12072-026-11112-5","url":null,"abstract":"<p><strong>Background: </strong>The relationship between steatotic liver disease (SLD) and dementia remains unclear, particularly regarding alcohol consumption patterns. We investigated the risk of dementia across SLD subtypes classified by alcohol consumption.</p><p><strong>Methods: </strong>We analyzed 3,071,829 adults without baseline dementia who underwent health examinations in 2012. Participants were classified into No SLD, metabolic dysfunction-associated steatotic liver disease (MASLD), metabolic dysfunction-associated alcohol-related liver disease (MetALD), and ALD groups. Primary outcomes were newly diagnosed all-cause dementia, Alzheimer's disease (AD), and vascular dementia (VD).</p><p><strong>Results: </strong>Over a median follow-up of 5.4 years, 72,545 all-cause dementia, 56,999 AD, and 8923 VD cases occurred. The risk of dementia significantly increased across all dementia outcomes in SLD (all p < 0.05). Across the SLD subtypes, ALD showed the highest risk of dementia, followed by MASLD, whereas MetALD showed largely neutral associations except for a modestly increased risk of VD. When MASLD was further stratified by alcohol consumption, the MASLD-no alcohol group showed consistently increased risk of all dementia outcomes (all p < 0.05). In contrast, MASLD with within-threshold alcohol intake showed heterogeneous associations across dementia outcomes.</p><p><strong>Conclusions: </strong>The association between SLD and dementia differed according to SLD phenotype and alcohol consumption pattern. These findings should be interpreted as observational associations and warrant further validation in studies with longitudinal assessment of SLD status and alcohol exposure.</p>","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":"1420-1431"},"PeriodicalIF":7.8,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148307033","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Clinical and pathological significance of serum anti-PD-1 autoantibodies in acute-onset and chronic autoimmune hepatitis.","authors":"Takashi Oda, Akinobu Takaki, Kenichi Harada, Teruko Arinaga-Hino, Masanori Abe, Takeshi Matsui, Atsushi Takahashi, Hiromasa Ohira, Yoshiyuki Suzuki, Nobuhiro Nakamoto, Atsushi Tanaka, Kazuyuki Matsumoto, Jinpeng Li, Nozomi Miyake, Masahiko Sue, Takuya Adachi, Yasuto Takeuchi, Hideki Onishi, Miwa Kawanaka, Motoyuki Otsuka","doi":"10.1007/s12072-026-11152-x","DOIUrl":"https://doi.org/10.1007/s12072-026-11152-x","url":null,"abstract":"<p><strong>Background: </strong>Acute-onset autoimmune hepatitis (A-AIH) poses diagnostic challenges because autoantibodies are frequently absent or serum IgG levels may only be mildly elevated. Autoantibodies against the immune checkpoint molecule PD-1 have been detected in patients with chronic AIH (C-AIH). To clarify the clinical and pathological significance of anti-PD-1 autoantibodies, we examined their association with the clinical features of patients with liver diseases, including A-AIH, C-AIH, primary biliary cholangitis (PBC), and drug-induced liver injury (DILI).</p><p><strong>Methods: </strong>We compared the clinical characteristics and serum anti-PD-1 autoantibody titers of patients with A-AIH, C-AIH, PBC, and DILI (n = 72, 45, 41, and 19, respectively). Correlations between autoantibody titers and biochemical parameters were assessed to identify the factors that discriminate between the diseases. To reduce non-specific IgG response, anti-PD-1 autoantibody titers were normalized to the serum IgG levels. The liver histology was evaluated in a subset of patients with AIH.</p><p><strong>Results: </strong>A-AIH caused severe liver parenchymal and portal inflammation. The anti-PD-1/IgG ratio showed positive correlations with AST and ALT, but only weak correlations with ALP and γ-GTP. Anti-PD-1/IgG ratio was the highest in A-AIH, followed by DILI, C-AIH and PBC. Histological findings showed that anti-PD-1/IgG ratio was associated with severe inflammation, but not with centrilobular necrosis.</p><p><strong>Conclusions: </strong>The serum anti-PD-1 autoantibody/IgG ratio was significantly elevated in A-AIH compared with that in C-AIH and PBC, and A-AIH was independently distinguished from C-AIH. These markers may assist with the assessment of acute-onset liver inflammation and clinical phenotyping of AIH.</p>","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":""},"PeriodicalIF":7.8,"publicationDate":"2026-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149080606","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Georg Kramer, Irina Andreea Lie-Ungurean, Benedikt Silvester Hofer, Lukas Hartl, Mathias Jachs, Lorenz Balcar, Georg Semmler, Christian Sebesta, Paul Thöne, Marlene Hintersteininger, Paula Höfinger, Rodrig Marculescu, Thomas Perkmann, Philipp Schwabl, Michael Trauner, Mattias Mandorfer, Thomas Reiberger, Benedikt Simbrunner
{"title":"Circulating fibronectin levels are linked to liver function, matrix remodeling, and hemostatic complications in advanced chronic liver disease.","authors":"Georg Kramer, Irina Andreea Lie-Ungurean, Benedikt Silvester Hofer, Lukas Hartl, Mathias Jachs, Lorenz Balcar, Georg Semmler, Christian Sebesta, Paul Thöne, Marlene Hintersteininger, Paula Höfinger, Rodrig Marculescu, Thomas Perkmann, Philipp Schwabl, Michael Trauner, Mattias Mandorfer, Thomas Reiberger, Benedikt Simbrunner","doi":"10.1007/s12072-026-11140-1","DOIUrl":"https://doi.org/10.1007/s12072-026-11140-1","url":null,"abstract":"<p><strong>Background and aims: </strong>Fibronectin is a multifunctional matrix glycoprotein involved in tissue remodeling and hemostasis; however, its clinical relevance in cirrhosis remains unclear. This study characterized circulating fibronectin across stages of advanced chronic liver disease (ACLD) and assessed its correlation to pathophysiological biomarkers and predictive value for liver-related complications.</p><p><strong>Methods: </strong>Patients with ACLD undergoing hepatic venous pressure gradient (HVPG) measurement were prospectively enrolled with circulating fibronectin measured simultaneously. Associations were assessed using correlation analyses and systems modeling. Competing-risk regression was used to evaluate clinical outcomes.</p><p><strong>Results: </strong>Among 298 patients (median HVPG 17 [12-21] mmHg; MELD 3.0 12 [9-17]), fibronectin levels were lower in decompensated than compensated ACLD (30.3 vs. 38.8 mg/dL; p < 0.001). Fibronectin correlated with hepatic synthesis (cholinesterase: Spearman's r = 0.64) and MELD 3.0 (r = - 0.47; both p < 0.001) while showing an independent positive association with ELF (β = 0.19; p < 0.001). In systems modeling, hepatic synthesis explained most of fibronectin variance (cholinesterase: 37%), followed by fibrinolysis (antiplasmin: 14%) and matrix remodeling (ELF: 12%). In exploratory analyses, higher fibronectin levels were independently associated with variceal bleeding (aSHR 1.04, p = 0.017), and lower fibronectin levels with portal vein thrombosis (aSHR 0.95, p = 0.031), when adjusted for HVPG, MELD 3.0, or IL-6. Fibronectin was not associated with other hepatic decompensation events, hepatocellular carcinoma, or liver-related mortality.</p><p><strong>Conclusion: </strong>Circulating fibronectin reflects hepatic synthetic capacity and matrix remodeling. Its divergent exploratory associations with variceal bleeding and portal vein thrombosis suggest that fibronectin may capture aspects of hemostatic vulnerability.</p><p><strong>Clinical trial number: </strong>NCT03267615.</p>","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":""},"PeriodicalIF":7.8,"publicationDate":"2026-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149060422","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Dynamic changes in controlled attenuation parameter (CAP) improve prognostic prediction for CHB patients with significant fibrosis and cirrhosis.","authors":"Xiaowei Ai, Mengyang Zhang, Shuyan Chen, Xinyu Zhao, Jialing Zhou, Tongtong Meng, Bingqiong Wang, Chenglin Sun, Xiao Han, Yankun Gao, Xiaoning Wu, Hong You, Yameng Sun","doi":"10.1007/s12072-026-11145-w","DOIUrl":"https://doi.org/10.1007/s12072-026-11145-w","url":null,"abstract":"<p><strong>Background & aims: </strong>The coexistence of hepatic steatosis and chronic hepatitis B (CHB) is becoming increasingly common. Although the controlled attenuation parameter (CAP) has been widely used to quantify hepatic steatosis in CHB patients, the prognostic value of longitudinal changes in CAP remains unknown. This study aimed to evaluate whether dynamic changes in CAP are associated with liver-related events (LREs) in CHB patients undergoing antiviral therapy.</p><p><strong>Methods: </strong>CHB patients with significant fibrosis or cirrhosis before antiviral therapy were included. CAP was used to assess hepatic steatosis. LREs were defined as hepatic decompensations, hepatocellular carcinoma (HCC), liver transplantation, or liver-related death. Joint models were employed to analyze associations between longitudinal measurements and risk of LREs.</p><p><strong>Results: </strong>A total of 573 CHB patients were followed for a median of 6.9 years, during which 51 LREs occurred. CAP-dynamics independently predicted LREs (per 10 dB/m increase aHR 0.86, 95% CI 0.78-0.96, p = 0.006). After adjusting for LSM-dynamics, CAP-dynamics remained an independent factor for LREs (per 10 dB/m increase aHR 0.85, 95% CI 0.77-0.95, p = 0.005). The multivariate joint model integrating CAP and LSM dynamics improved predictive performance compared with LSM alone, with the 7-year AUROC increasing from 0.70 to 0.75. CAP exceeding 236 dB/m over time was associated with a reduced risk of LREs (aHR 0.67, 95% CI 0.53-0.84, p < 0.001).</p><p><strong>Conclusion: </strong>In on-treatment CHB patients with significant fibrosis, the dynamics of CAP were associated with the risk of LREs. Longitudinal monitoring of CAP can offer extra prognostic value.</p>","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":""},"PeriodicalIF":7.8,"publicationDate":"2026-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149008435","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Gediz Dogay Us, Francesco Innocenti, Ozgur Muhammet Koc, Sevval İlke Ebeoglu, Baris Okcun, İhsan Nuri Akpinar, Melih Hulusi Us, Ger H Koek
{"title":"Coronary atherosclerosis across stages of metabolic dysfunction-associated steatotic liver disease: a VCTE-CCTA study.","authors":"Gediz Dogay Us, Francesco Innocenti, Ozgur Muhammet Koc, Sevval İlke Ebeoglu, Baris Okcun, İhsan Nuri Akpinar, Melih Hulusi Us, Ger H Koek","doi":"10.1007/s12072-026-11147-8","DOIUrl":"https://doi.org/10.1007/s12072-026-11147-8","url":null,"abstract":"<p><strong>Background: </strong>Metabolic dysfunction-associated steatotic liver disease (MASLD) and coronary artery disease (CAD) share common pathophysiologic pathways. However, the relationship between different stages of MASLD and distinct coronary atherosclerosis phenotypes remains unclear. We evaluated the association of hepatic steatosis and fibrosis with coronary artery disease outcomes using paired vibration-controlled transient elastography (VCTE) and coronary computed tomography angiography (CCTA).</p><p><strong>Methods: </strong>425 adults who underwent both VCTE and CCTA within a three-month interval were included. MASLD was defined as controlled attenuation parameter (CAP) ≥248 dB/m, and significant fibrosis was defined as Liver Stiffness Measurement (LSM) ≥8 kPa. Coronary outcomes were assessed according to Coronary Artery Disease Reporting and Data System guidance. The primary outcome was plaque presence; secondary outcomes included obstructive stenosis, calcified plaque, high segment involvement, and CAD severity. Multivariable logistic regression models were progressively adjusted for demographic, lifestyle, and cardiometabolic factors.</p><p><strong>Results: </strong>MASLD was present in 47.3% of participants. Individuals with MASLD had a higher prevalence of overall plaque than those without (81.6% vs 60.7%, p<0.001), whereas obstructive stenosis did not differ between groups. MASLD was independently associated with higher odds of overall plaque presence after full adjustment (OR 2.22, 95% CI 1.04-4.73; p=0.038). In exploratory analyses, MASLD did not increase the odds of obstructive stenosis, calcified plaque, or CAD severity. In contrast, 1 kPa increase in LSM was associated with higher odds of obstructive stenosis (OR 1.14, 95% CI 1.00-1.30) and calcified plaque (OR 1.18, 95% CI 1.04-1.34), but not CAD presence and severity.</p><p><strong>Conclusion: </strong>MASLD was independently associated with the presence of coronary atherosclerotic plaque. Exploratory analyses further suggested that greater liver stiffness may be associated with obstructive stenosis and calcified plaque, raising the possibility that more advanced liver disease relates to specific features of advanced coronary artery disease. Confirmation in larger prospective studies is warranted.</p>","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":""},"PeriodicalIF":7.8,"publicationDate":"2026-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148982555","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}